Solar stocks surge after Treasury tightens clean energy tax credit rules
PHILADELPHIA/VANCOUVER - BriaCell Therapeutics Corp. (Nasdaq:BCTX, TSX: BCT), a clinical-stage biotechnology company with a market capitalization of $2.5 million, has been accepted into Memorial Sloan Kettering Cancer Center’s Therapeutics Accelerator 2025 Cohort program, the company announced Wednesday. According to InvestingPro data, analysts anticipate significant sales growth for BriaCell in the current year, with revenue projected to increase by 133%.
The collaboration aims to accelerate the clinical development of Bria-OTS+, BriaCell’s next generation personalized off-the-shelf immunotherapy for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers.
Through the program, BriaCell will explore access to MSK’s expertise and institutional resources, including GMP manufacturing services, Investigational New Drug Application preparation and submission, and regulatory strategy support. This collaboration comes at a crucial time as InvestingPro analysis indicates the company is rapidly burning through cash, with a weak overall financial health score of 1.38.
"We are honored to work with the scientific and clinical experts at MSK Therapeutics Accelerator," said Dr. William V. Williams, BriaCell’s President and CEO, in a press release statement.
Eileen Flowers, PhD, Director of Technology Development & Licensing in the Office of Entrepreneurship and Commercialization at MSK, confirmed the acceptance of BriaCell into the cohort program.
Memorial Sloan Kettering Cancer Center has more than 135 years of experience in cancer research and treatment, providing BriaCell with access to established expertise in cancer therapy development.
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment.
The announcement contains forward-looking statements regarding the potential benefits of the collaboration, which are subject to risks and uncertainties as outlined in the company’s regulatory filings. InvestingPro subscribers can access additional insights, including 5 more key ProTips and comprehensive financial metrics to better evaluate BriaCell’s investment potential.
In other recent news, BriaCell Therapeutics Corp. announced that UCLA Health Jonsson Comprehensive Cancer Center has joined its Phase 3 clinical study for advanced metastatic breast cancer. This study, named Bria-ABC, evaluates Bria-IMT in combination with a checkpoint inhibitor against the physician’s choice of treatment. Additionally, the company reported a 52% one-year survival rate in its Phase 2 clinical study, which exceeds expectations compared to current standard therapies. BriaCell has also expanded its Phase 3 study by adding Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven, bringing the total to 58 active clinical sites. The study will continue without modifications following a positive safety review by the independent Data Safety Monitoring Board. In another development, BriaCell has been granted a New Zealand patent for its whole-cell cancer immunotherapy technology, providing exclusivity until February 27, 2037. These recent developments highlight BriaCell’s ongoing efforts in the field of cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.